[In vitro study on the effects of the novel retinoids combined with IFN-gamma on the proliferation and differentiation of fresh acute monocytic leukemic cells].
To investigate the prospect for clinical use of novel retinoids YS 904012 and R 9158 in combination with IFN-gamma in inducing differentiation of acute monocytic leukemia. The effects of novel retinoids with IFN-gamma on the differentiation and clonal proliferation of fresh leukemia cell from 6 monocytic leukemia patients were studied in vitro. Cell morphological examination, nitro tetrazolium blue reduction test and DCE, expression of CD14 and CD68 and CFU-L were used in the study. The primary leukemia cell, cultured with the combination of YS 904012 and IFN-gamma, became more mature in morphology. The NBT reduction rate and DCE were increased from 23.4% and 25.0% to 61.5% and 52.0%, respectively. The expression of CD14 and CD68 was increased. The growth of the leukemic colony in semi-solid culture was markedly inhibited. The activity of YS 904012 combined with IFN-gamma in inhibiting proliferation and inducing differentiation of monoblast was greater than that of R9158 or all-trans retinoic acid in combination with IFN-gamma (P < 0.01). The YS 904012 combined with IFN-gamma is worthy of further study for clinical differentiation therapy of acute monocytic leukemia.